Aeterna, Shareholders Reach $6.5M Hormone Drug Deal
Investors in biopharmaceutical company Aeterna Zentaris Inc. asked a New Jersey federal judge Thursday to approve a $6.5 million deal to end class action allegations that the company lied about the...To view the full article, register now.
Already a subscriber? Click here to view full article